Targets › IFNA2
1 program from 1 company in 5 trials: 4 Phase 3, 1 Phase 1; Oncology; next expected readout Jun 2028.
Produced by macrophages, IFN-alpha have antiviral activities. (UniProt, P01563)
Open in Phaseline: the race on IFNA2, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Ferring Pharmaceuticals | Nadofaragene Firadenovec Interferon alpha-2 exogenous gene | IFNA2 | Phase 3 | Non-muscle Invasive Bladder Cancer With Carcinoma in Situ; Intermediate Risk Non-Muscle Invasive Bladder Cancer; Bladder Cancer; Low-grade Upper Tract Urothelial Carcinoma … | Jun 2028 |
Non-muscle Invasive Bladder Cancer With Carcinoma in Situ (1) Intermediate Risk Non-Muscle Invasive Bladder Cancer (1) Bladder Cancer (1) Low-grade Upper Tract Urothelial Carcinoma (1) Non-Muscle Invasive Bladder Cancer (1)
other (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.